180 related articles for article (PubMed ID: 16823921)
1. The use of oil adjuvants in therapeutic vaccines.
Aucouturier J; Ascarateil S; Dupuis L
Vaccine; 2006 Apr; 24 Suppl 2():S2-44-5. PubMed ID: 16823921
[TBL] [Abstract][Full Text] [Related]
2. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines.
Aucouturier J; Dupuis L; Deville S; Ascarateil S; Ganne V
Expert Rev Vaccines; 2002 Jun; 1(1):111-8. PubMed ID: 12908518
[TBL] [Abstract][Full Text] [Related]
3. Assessment of efficacy and safety of various adjuvant formulations with a total soluble extract of Trichinella spiralis.
Aucouturier J; Deville S; Perret C; Vallée I; Boireau P
Parasite; 2001 Jun; 8(2 Suppl):S126-32. PubMed ID: 11484335
[TBL] [Abstract][Full Text] [Related]
4. A review of the current status of oil adjuvants in foot--and--mouth disease vaccines.
McKercher PD; Graves JH
Dev Biol Stand; 1976; 35():107-12. PubMed ID: 198275
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of novel PGM-containing incomplete Seppic adjuvants in rabbits.
Halassy B; Vdović V; Habjanec L; Balija ML; Gebauer B; Sabioncello A; Santek T; Tomasić J
Vaccine; 2007 Apr; 25(17):3475-81. PubMed ID: 17239503
[TBL] [Abstract][Full Text] [Related]
6. Comparison of mouse and rabbit model for the assessment of strong PGM-containing oil-based adjuvants.
Habjanec L; Halassy B; Vdović V; Balija ML; Tomasić J
Vet Immunol Immunopathol; 2008 Feb; 121(3-4):232-40. PubMed ID: 17996307
[TBL] [Abstract][Full Text] [Related]
7. Adjuvants designed for veterinary and human vaccines.
Aucouturier J; Dupuis L; Ganne V
Vaccine; 2001 Mar; 19(17-19):2666-72. PubMed ID: 11257407
[TBL] [Abstract][Full Text] [Related]
8. CpG-mediated augmentation of CD8+ T-cell responses in mice is attenuated by a water-in-oil emulsion (Montanide ISA-51) but enhanced by an oil-in-water emulsion (IDRI SE).
Makinen SR; Zhu Q; Davis HL; Weeratna RD
Int Immunol; 2016 Sep; 28(9):453-61. PubMed ID: 27055469
[TBL] [Abstract][Full Text] [Related]
9. Oil-based emulsion vaccine adjuvants.
Schijns VEJC; Strioga M; Ascarateil S
Curr Protoc Immunol; 2014 Aug; 106():2.18.1-2.18.7. PubMed ID: 25081910
[TBL] [Abstract][Full Text] [Related]
10. Identification of potent biodegradable adjuvants that efficiently break self-tolerance--a key issue in the development of therapeutic vaccines.
Ringvall M; Huijbers EJ; Ahooghalandari P; Alekseeva L; Andronova T; Olsson AK; Hellman L
Vaccine; 2009 Dec; 28(1):48-52. PubMed ID: 19835827
[TBL] [Abstract][Full Text] [Related]
11. Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations.
Miles AP; McClellan HA; Rausch KM; Zhu D; Whitmore MD; Singh S; Martin LB; Wu Y; Giersing BK; Stowers AW; Long CA; Saul A
Vaccine; 2005 Mar; 23(19):2530-9. PubMed ID: 15752840
[TBL] [Abstract][Full Text] [Related]
12. Adjuvants--a balance between toxicity and adjuvanticity.
Gupta RK; Relyveld EH; Lindblad EB; Bizzini B; Ben-Efraim S; Gupta CK
Vaccine; 1993; 11(3):293-306. PubMed ID: 8447157
[TBL] [Abstract][Full Text] [Related]
13. Comparison of tissue reactions produced by Haemophilus pleuropneumoniae vaccines made with six different adjuvants in swine.
Straw BE; MacLachlan NJ; Corbett WT; Carter PB; Schey HM
Can J Comp Med; 1985 Apr; 49(2):149-51. PubMed ID: 4016580
[TBL] [Abstract][Full Text] [Related]
14. The effects of repeated injections of certain adjuvants on chemical carcinogenesis.
Bingham E; Stemmer KL; Falk HL
Ann Allergy; 1967 Dec; 25(12):684-90. PubMed ID: 6060068
[No Abstract] [Full Text] [Related]
15. An overview of adjuvants utilized in prophylactic vaccine formulation as immunomodulators.
Chauhan N; Tiwari S; Iype T; Jain U
Expert Rev Vaccines; 2017 May; 16(5):491-502. PubMed ID: 28285554
[TBL] [Abstract][Full Text] [Related]
16. Adjuvants for human vaccines--current status, problems and future prospects.
Gupta RK; Siber GR
Vaccine; 1995 Oct; 13(14):1263-76. PubMed ID: 8585280
[TBL] [Abstract][Full Text] [Related]
17. Newcastle disease oil emulsion vaccines prepared with animal, vegetable, and synthetic oils.
Stone HD
Avian Dis; 1997; 41(3):591-7. PubMed ID: 9356704
[TBL] [Abstract][Full Text] [Related]
18. Oil-in-water liposomal emulsions: characterization and potential use in vaccine delivery.
Muderhwa JM; Matyas GR; Spitler LE; Alving CR
J Pharm Sci; 1999 Dec; 88(12):1332-9. PubMed ID: 10585231
[TBL] [Abstract][Full Text] [Related]
19. Adjuvants in veterinary vaccines: modes of action and adverse effects.
Spickler AR; Roth JA
J Vet Intern Med; 2003; 17(3):273-81. PubMed ID: 12774966
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory activity of novel adjuvant formulations based on Montanide ISA oil-based adjuvants and peptidoglycan monomer.
Habjanec L; Halassy B; Tomasić J
Int Immunopharmacol; 2008 May; 8(5):717-24. PubMed ID: 18387514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
